Market Overview:
The global RNA polymerase inhibitor market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising demand for targeted therapies, and growing preference for oral therapies. Based on type, the global RNA polymerase inhibitor market is segmented into veliparib, rucaparib, talazoparib, niraparib and others. Veliparib is expected to account for a major share of the global RNA polymerase inhibitor market during the forecast period owing to its high efficacy and safety profile. Niraparib is also anticipated to witness significant growth during the forecast period due its strong clinical data and better patient tolerability as compared with other drugs in this class. Based on application, the global RNA polymerase inhibitor market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Hospital pharmacies are estimated to account for a majority share of this market during the forecast period owing to increased use of these drugs in combination with other chemotherapeutic agents for treatment of various cancers.
Product Definition:
A RNA polymerase inhibitor is a molecule that blocks the action of RNA polymerase. This can be used to stop or regulate gene expression.
Veliparib:
Veliparib is a drug that inhibits the DNA-based RNA polymerase. It works by blocking the action of PARP (poly ADP ribose polymerase) enzyme, which is involved in cell proliferation and division. The drug has shown to be effective in patients with advanced non-small cell lung cancer (NSCLC), but it has not been found to be useful for other types of cancers such as breast or prostate cancer.
Rucaparib:
Rucaparib is a drug used for the treatment of chronic myeloid leukemia. Chronic myeloid leukemia (CML) is a type of blood cancer that develops in the bone marrow and lymphatic system due to an abnormal gene called BCR-ABL1. The presence of rucaparib molecule in the body, it interferes with DNA synthesis and hence blocks cell growth.
Application Insights:
Based on the application, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacy segment dominated the global RNA polymerase inhibitor market in 2017 owing to an increase in cancer cases and rising awareness about available treatment options. Hospital pharmacists are playing a significant role in providing information related to drug therapies for patients so that they can make informed decisions regarding their healthcare needs. As a result, this vertical is expected to continue its dominance over the forecast period due to factors such as increasing demand for cost-effective drugs among hospitals across various regions globally.
The online pharmacy segment is anticipated register notable growth during the forecast period owing to factors such as high accessibility of internet cafĩs and proliferation of e-commerce portals worldwide coupled with growing concerns regarding patient safety while purchasing medicines from non-authorized sources over the internet.
Regional Analysis:
North America dominated the global RNA polymerase inhibitor market in 2017. This is due to the presence of major players, availability of effective treatment methods and high adoption rate for new therapies among patients. Moreover, increasing incidence of cancer is also one of the major factors responsible for its largest share. For instance, according to statistics provided by American Cancer Society in 2018, around 1,735,780 people were diagnosed with new cases of cancer in U.S., and it is estimated that 600960 individuals died due to this disease during the same year.
Growth Factors:
- Increasing demand for RNA Polymerase Inhibitor drugs due to rising incidence of cancer
- Growing investment in research and development of new RNA Polymerase Inhibitor drugs
- Rising number of mergers and acquisitions in the RNA Polymerase Inhibitor market
- Proliferation of generic players in the market
- Technological advancements in the field of RNA Polymerase Inhibitors
Scope Of The Report
Report Attributes
Report Details
Report Title
RNA Polymerase Inhibitor Market Research Report
By Type
Veliparib, Rucaparib, Talazoparib, Niraparib, Others
By Application
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
Johnson & Johnson, AstraZeneca, AbbVie, Bristol Myers Squibb, Repare Therapeutics, Merck, Genentech, Artios Pharma, Pfizer, Sierra Oncology, Johnson & Johnson, Clovis Oncology, Karyopharm Therapeutics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
124
Number of Tables & Figures
87
Customization Available
Yes, the report can be customized as per your need.
Global RNA Polymerase Inhibitor Market Report Segments:
The global RNA Polymerase Inhibitor market is segmented on the basis of:
Types
Veliparib, Rucaparib, Talazoparib, Niraparib, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Johnson & Johnson
- AstraZeneca
- AbbVie
- Bristol Myers Squibb
- Repare Therapeutics
- Merck
- Genentech
- Artios Pharma
- Pfizer
- Sierra Oncology
- Johnson & Johnson
- Clovis Oncology
- Karyopharm Therapeutics
Highlights of The RNA Polymerase Inhibitor Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Veliparib
- Rucaparib
- Talazoparib
- Niraparib
- Others
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the RNA Polymerase Inhibitor Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
RNA polymerase inhibitors (RPI) are a type of drug that blocks the activity of RNA polymerase, an enzyme responsible for copying DNA into RNA. RPI drugs can be used to treat various types of cancer, including leukemia and lymphoma.
Some of the major players in the rna polymerase inhibitor market are Johnson & Johnson, AstraZeneca, AbbVie, Bristol Myers Squibb, Repare Therapeutics, Merck, Genentech, Artios Pharma, Pfizer, Sierra Oncology, Johnson & Johnson, Clovis Oncology, Karyopharm Therapeutics.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 RNA Polymerase Inhibitor Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 RNA Polymerase Inhibitor Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 RNA Polymerase Inhibitor Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the RNA Polymerase Inhibitor Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global RNA Polymerase Inhibitor Market Size & Forecast, 2018-2028
4.5.1 RNA Polymerase Inhibitor Market Size and Y-o-Y Growth
4.5.2 RNA Polymerase Inhibitor Market Absolute $ Opportunity
Chapter 5 Global RNA Polymerase Inhibitor Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 RNA Polymerase Inhibitor Market Size Forecast by Type
5.2.1 Veliparib
5.2.2 Rucaparib
5.2.3 Talazoparib
5.2.4 Niraparib
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global RNA Polymerase Inhibitor Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 RNA Polymerase Inhibitor Market Size Forecast by Applications
6.2.1 Hospital Pharmacies
6.2.2 Retail Pharmacies
6.2.3 Online Pharmacies
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global RNA Polymerase Inhibitor Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 RNA Polymerase Inhibitor Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America RNA Polymerase Inhibitor Analysis and Forecast
9.1 Introduction
9.2 North America RNA Polymerase Inhibitor Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America RNA Polymerase Inhibitor Market Size Forecast by Type
9.6.1 Veliparib
9.6.2 Rucaparib
9.6.3 Talazoparib
9.6.4 Niraparib
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America RNA Polymerase Inhibitor Market Size Forecast by Applications
9.10.1 Hospital Pharmacies
9.10.2 Retail Pharmacies
9.10.3 Online Pharmacies
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe RNA Polymerase Inhibitor Analysis and Forecast
10.1 Introduction
10.2 Europe RNA Polymerase Inhibitor Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe RNA Polymerase Inhibitor Market Size Forecast by Type
10.6.1 Veliparib
10.6.2 Rucaparib
10.6.3 Talazoparib
10.6.4 Niraparib
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe RNA Polymerase Inhibitor Market Size Forecast by Applications
10.10.1 Hospital Pharmacies
10.10.2 Retail Pharmacies
10.10.3 Online Pharmacies
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific RNA Polymerase Inhibitor Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific RNA Polymerase Inhibitor Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific RNA Polymerase Inhibitor Market Size Forecast by Type
11.6.1 Veliparib
11.6.2 Rucaparib
11.6.3 Talazoparib
11.6.4 Niraparib
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific RNA Polymerase Inhibitor Market Size Forecast by Applications
11.10.1 Hospital Pharmacies
11.10.2 Retail Pharmacies
11.10.3 Online Pharmacies
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America RNA Polymerase Inhibitor Analysis and Forecast
12.1 Introduction
12.2 Latin America RNA Polymerase Inhibitor Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America RNA Polymerase Inhibitor Market Size Forecast by Type
12.6.1 Veliparib
12.6.2 Rucaparib
12.6.3 Talazoparib
12.6.4 Niraparib
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America RNA Polymerase Inhibitor Market Size Forecast by Applications
12.10.1 Hospital Pharmacies
12.10.2 Retail Pharmacies
12.10.3 Online Pharmacies
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) RNA Polymerase Inhibitor Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) RNA Polymerase Inhibitor Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) RNA Polymerase Inhibitor Market Size Forecast by Type
13.6.1 Veliparib
13.6.2 Rucaparib
13.6.3 Talazoparib
13.6.4 Niraparib
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) RNA Polymerase Inhibitor Market Size Forecast by Applications
13.10.1 Hospital Pharmacies
13.10.2 Retail Pharmacies
13.10.3 Online Pharmacies
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 RNA Polymerase Inhibitor Market: Competitive Dashboard
14.2 Global RNA Polymerase Inhibitor Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Johnson & Johnson
14.3.2 AstraZeneca
14.3.3 AbbVie
14.3.4 Bristol Myers Squibb
14.3.5 Repare Therapeutics
14.3.6 Merck
14.3.7 Genentech
14.3.8 Artios Pharma
14.3.9 Pfizer
14.3.10 Sierra Oncology
14.3.11 Johnson & Johnson
14.3.12 Clovis Oncology
14.3.13 Karyopharm Therapeutics
